Replies to post #5117 on Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

ENTA reports FY4Q25* results—extends cash-runway guidance_one_year:

https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-reports-financial-results-its-fiscal-45

• 9/30/25 cash = $188.91M, an increase of $15.2M from 6/30/25. Note: The $188.9M figure excludes the $70.3M of net proceeds from the public offering that closed on 10/2/25 (after the end of the fiscal quarter).

• ENTA lengthened its cash-runway guidance by one year. The new guidance is that cash on hand and expected royalty revenue are sufficient to fund operations “into FY2029”, which starts on 10/1/28. (The old guidance was “into FY2028”.)

• FY4Q25 gross Mavyret royalty revenue was $15.1M, +3% YoY. Please see #msg-176309105 for related info.

• FY4Q25 R&D expenses were $23.8M, -13% QoQ and -23% YoY.

• FY4Q25 SG&A expenses were $9.7M, -3% QoQ and -29% YoY.

*Fiscal year 2025 ended on 9/30/25.